PMID- 36776192
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230214
IS  - 2229-5178 (Print)
IS  - 2249-5673 (Electronic)
IS  - 2229-5178 (Linking)
VI  - 14
IP  - 1
DP  - 2023 Jan-Feb
TI  - Biologicals in Treatment of Chronic Urticaria: A Narrative Review.
PG  - 9-20
LID - 10.4103/idoj.idoj_145_22 [doi]
AB  - Chronic urticaria is a common inflammatory skin disease affecting around 0.5-1% 
      of the world's population. The disease has a chronic indolent course which 
      significantly affects the patient's quality of life. Urticaria pathogenesis 
      involves cross-linking of immunoglobulin E (IgE) on mast cells causing 
      degranulation which occurs by various pathways which leads to development of 
      wheals and angioedema. The first-line treatment for chronic urticaria is 
      non-sedating second-generation H1 antihistamines (AHs). After the advent of 
      anti-IgE monoclonal antibody omalizumab, the response rate in resistant urticaria 
      has improved significantly without any major adverse events. Other biologicals 
      such as anti-IgE, anti-IL-5, anti-IL-1, anti-IL-17, and anti-CD20 monoclonal 
      antibodies are under trial. These biologicals have better efficacy and safety 
      profile as compared to conventional immunosuppressants. Even with the advances in 
      the last decade, recurrence after stopping the therapy is common, and there is a 
      need for better understanding of the pathogenesis and the drugs acting on the key 
      pathways involved in urticaria. In this review, we provide the role of several 
      biologicals in the treatment of chronic urticaria.
CI  - Copyright: (c) 2022 Indian Dermatology Online Journal.
FAU - Mustari, Akash P
AU  - Mustari AP
AD  - Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
FAU - Bishnoi, Anuradha
AU  - Bishnoi A
AD  - Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
FAU - Kumaran, Muthu Sendhil
AU  - Kumaran MS
AD  - Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221214
PL  - India
TA  - Indian Dermatol Online J
JT  - Indian dermatology online journal
JID - 101586880
PMC - PMC9910522
OTO - NOTNLM
OT  - Biologicals
OT  - chronic urticarial
OT  - novel biologics
OT  - omalizumab
OT  - resistant urticaria
COIS- There are no conflicts of interest.
EDAT- 2023/02/14 06:00
MHDA- 2023/02/14 06:01
PMCR- 2022/12/14
CRDT- 2023/02/13 03:15
PHST- 2022/03/04 00:00 [received]
PHST- 2022/07/23 00:00 [revised]
PHST- 2022/08/04 00:00 [accepted]
PHST- 2023/02/13 03:15 [entrez]
PHST- 2023/02/14 06:00 [pubmed]
PHST- 2023/02/14 06:01 [medline]
PHST- 2022/12/14 00:00 [pmc-release]
AID - IDOJ-14-9 [pii]
AID - 10.4103/idoj.idoj_145_22 [doi]
PST - epublish
SO  - Indian Dermatol Online J. 2022 Dec 14;14(1):9-20. doi: 10.4103/idoj.idoj_145_22. 
      eCollection 2023 Jan-Feb.